Search
SOLACI Congress
HomePeripheral vascular diseaseFemoropopliteal

Femoropopliteal

View Category

Femoropopliteal

Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and...
solaci -
Learn More
Femoropopliteal

IN.PACT Global: Follow Up of Real-Life Patient in Femoropopliteal Territory

Drug coated balloons (DCB) emerged as an innovative treatment approximately 10 years ago. Since then, numerous randomized...
solaci -
Learn More
Femoropopliteal

Should We Start Stenting with DES in Femoropopliteal Territory?

Percutaneous intervention of femoropopliteal lesions have been the standard strategy these past two decades. The development of...
solaci -
Learn More
Femoropopliteal

IVUS in Femoropopliteal PCI: Should We Start Using It?

For approximately two decades now, PCI has been the treatment of choice in femoropopliteal territory, and even...
solaci -
Learn More
Femoropopliteal

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD)....
solaci -
Learn More
Femoropopliteal

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite...
solaci -
Learn More
Femoropopliteal

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between...
solaci -
Learn More
Femoropopliteal

SOLACI PERIPHERAL | 6th Clinical Case: Common, Superficial and Deep Femoral Artery Recanalization

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Ana Paula Mollón (Arg.) presents “Common, Superficial...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Dr. Carlos Fava - 0
Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

Institutional News

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy